Multiple myeloma is incurable, and patients can eventually become refractory to multiple classes of treatment
Proteasome inhibitors
Immunomodulatory agents
Anti-CD38 monoclonal antibodiesPatients with triple-class refractory multiple myeloma can have more progressive disease, poor prognosis, and few treatment options remaining.
Patients can continue to progress and require additional therapies.1,3,4
CD38, cluster of differentiation 38.
References:
- Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):1-7.
- Bruno AS, Willson JL, Opalinska JM, et al. Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma. Expert Rev Hematol. 2020;13(9):1017-1025.
- Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101(4):396-406.
- Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol.
2016;175(2):252-264.
